| Bioactivity | Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects[1]. |
| Invitro | Benufutamab (GEN1029; HexaBody-DR5/DR5; 20 µg/mL; 24 hours) induces potent cytotoxicity in multiple myeloma (MM) cells[1]. Cell Viability Assay[1] Cell Line: |
| Name | Benufutamab |
| CAS | 2109730-69-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |